Completely agree with you. I was trying to find expected (or current) response rates in GBM specific treatments as well to try and get a better picture of what the medical field sort of expect from the current standard of care. Like you say, it's still hard to compare when there really is nothing out there, in the area of CAR T and GBM, to compare to.
I also found it interesting to read the definition of stable disease...
"Cancer doctors use the term stable disease to describe a tumor that is neither growing nor shrinking. Specifically, it means that there was neither an increase in size of more than 20% nor a decrease in size of more than 30% since the initial baseline measurement."
It would be great to get some more details from trial updates on what side of the fence these patients with stable disease sat on in the first cohort. Was it a sub-20% increase in tumor size or a sub-30% decrease in tumor size?
One other thing I found was a study utilising CAR T cell therapy (can't remember which one now) that actually showed an initial disease PROGRESSION in early phases of treatment before the tumors then started to decrease significantly in subsequent doses with some promising final ORR stats. Just goes to show that new treatment protocols can be so unpredictable throughout trials and to just follow the science as it unfolds.
